Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer
NCT03803475Phase 3Completed
- Start
- Oct 2018
- Primary completion
- Aug 2020
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa). Primary endpoints: Detection Rate of PSMA-11 PET for Positive Disease by Prostate Specific Antigen (PSA) Group at 1 day, Detection Rate of PSMA-11 PET for Positive Disease in Prostate Bed by PSA Group at 1 day and 3 more. Started Oct 2018; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03803475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03803475.